Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 6.1% – Should You Sell?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH)’s stock price traded down 6.1% on Thursday . The company traded as low as $43.80 and last traded at $43.4780. 47,807 shares were traded during trading, a decline of 94% from the average session volume of 781,570 shares. The stock had previously closed at $46.29.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. Wedbush restated an “outperform” rating and issued a $46.00 price objective on shares of Dianthus Therapeutics in a research note on Monday, December 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Wednesday, October 8th. HC Wainwright upped their price objective on Dianthus Therapeutics from $40.00 to $47.00 and gave the company a “buy” rating in a research note on Monday, November 10th. Finally, Truist Financial increased their price objective on Dianthus Therapeutics from $56.00 to $63.00 and gave the stock a “buy” rating in a research report on Thursday, January 8th. Eight investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $64.43.

Dianthus Therapeutics Trading Down 6.2%

The business’s 50 day simple moving average is $41.28 and its two-hundred day simple moving average is $32.62. The firm has a market capitalization of $1.86 billion, a P/E ratio of -12.47 and a beta of 1.55.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its earnings results on Wednesday, November 5th. The company reported ($0.97) EPS for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.11). The business had revenue of $0.40 million during the quarter, compared to the consensus estimate of $0.58 million. Dianthus Therapeutics had a negative return on equity of 33.02% and a negative net margin of 4,106.04%. Analysts predict that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Insider Activity

In other news, CFO Ryan Savitz sold 20,000 shares of the firm’s stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $45.18, for a total transaction of $903,600.00. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Simrat Randhawa sold 109,031 shares of the business’s stock in a transaction on Friday, November 14th. The shares were sold at an average price of $38.14, for a total transaction of $4,158,442.34. Following the sale, the executive vice president owned 4,000 shares of the company’s stock, valued at approximately $152,560. This represents a 96.46% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 216,538 shares of company stock worth $8,283,175 in the last 90 days. Company insiders own 8.15% of the company’s stock.

Hedge Funds Weigh In On Dianthus Therapeutics

Institutional investors have recently made changes to their positions in the business. Fairmount Funds Management LLC grew its position in Dianthus Therapeutics by 22.2% during the third quarter. Fairmount Funds Management LLC now owns 3,307,191 shares of the company’s stock valued at $130,138,000 after buying an additional 600,000 shares during the period. Vestal Point Capital LP boosted its stake in shares of Dianthus Therapeutics by 88.2% during the 2nd quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock worth $59,616,000 after acquiring an additional 1,499,931 shares during the last quarter. Wellington Management Group LLP grew its position in shares of Dianthus Therapeutics by 3,366.9% during the 3rd quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company’s stock valued at $101,431,000 after acquiring an additional 2,503,311 shares during the period. TCG Crossover Management LLC grew its position in shares of Dianthus Therapeutics by 11.7% during the 3rd quarter. TCG Crossover Management LLC now owns 1,676,624 shares of the company’s stock valued at $65,975,000 after acquiring an additional 175,000 shares during the period. Finally, Vanguard Group Inc. increased its stake in shares of Dianthus Therapeutics by 13.6% in the 3rd quarter. Vanguard Group Inc. now owns 1,642,198 shares of the company’s stock worth $64,620,000 after purchasing an additional 196,117 shares in the last quarter. Institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.